Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire
Hepatitis C virus in Asia: utility values based on the Short Form-36 questionnaire
复制标题
亚洲的丙型肝炎病毒：基于 Short Form-36 调查问卷的效用值
DOI：
--
复制
发表时间：
2012
影响因子：
2.3
通讯作者：
C. Leteneux
中科院分区：
文献类型：
--
作者：
B. Crawford;C. Yeung;E. Tanaka;M. Kraemer;C. Leteneux
在对卫生经济评估的需求日益增长的亚洲，公用事业数据很重要。通过四种语言的国际和本地书目数据库进行了文献综述，以评估亚洲慢性丙型肝炎（CHC）患者的效用。结果表明，对亚洲CHC人文负担的研究较为缺乏。通过绘制地图，估计亚洲CHC患者的效用在0.68至0.86之间。CHC患者的效用低于健康对照组，差异在0.032 ~ 0.261单位之间。对于没有持续病毒学反应的受试者，治疗效用值下降了0.07-0.13个单位，对于持续病毒学反应的受试者，治疗效用值下降了0.03-0.06个单位。研究结果提供了亚洲CHC患者效用价值的实证数据，可用于未来的成本效益分析或卫生技术评估。
Utility data are important in Asia, where the need for health economic evaluations is growing. A literature review was conducted across international and local bibliographical databases in four languages to evaluate the utilities for chronic hepatitis C (CHC) patients in Asia. The results showed a lack of research on the humanistic burden of CHC in Asia. Using mapping, the estimated utilities for CHC patients in Asia ranged between 0.68 and 0.86. The utilities of CHC patients were lower than that of healthy controls, with the differences ranging between 0.032 and 0.261 units. On-treatment utility values declined by 0.07–0.13 units for subjects without sustained virological response and by 0.03–0.06 units for sustained virological response subjects. The results provide empirical data on utility values among CHC patients in Asia that can be used in future cost–effectiveness analysis or health technology assessment.